


This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

- 1. (Currently Amended)** A pharmaceutical composition, which is in the form of an inhalable aerosol, solution or suspension, comprising:


one or more anticholinergics of formula **1**



wherein

X<sup>-</sup> denotes an anion with a single negative charge,

one or more PDE-IV inhibitors, (**2**), selected from enprofylline, theophylline, roflumilast, ~~Bay 198004, CP 325,366, BY343, D 4396 (Seh 351591), V 11294A, AWD 12-281,~~ methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzo-furan-6-yl ester, tofigamist, pumafentrine, (3-(3-cyclopentyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H purine hydrochloride), N-(3,5-dichloro-1-oxidopyridin-4-yl)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide, (N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide), N-(3,5-dichloro-1-oxo-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide and the tricyclic nitrogen heterocycles of formula **2a**



wherein

$R^1$  is  $C_1$ - $C_5$ -alkyl,  $C_5$ - $C_6$ -cycloalkyl, phenyl, benzyl or a 5- or 6-membered, saturated or unsaturated heterocyclic ring which contains one or two heteroatoms selected from oxygen and nitrogen;

$R^2$  is  $C_1$ - $C_5$ -alkyl or  $C_2$ - $C_4$ -alkenyl;

$R^3$  is  $C_1$ - $C_5$ -alkyl which is optionally substituted by  $C_1$ - $C_4$ -alkoxy,  $C_5$ - $C_6$ -cycloalkyl, phenoxy or a 5- or 6-membered, saturated or unsaturated heterocyclic ring which contains one or two heteroatoms selected from oxygen and nitrogen;  $C_5$ - $C_6$ -cycloalkyl, phenyl or benzyl, each optionally substituted by  $C_1$ - $C_4$ -alkoxy,

each optionally in the form of a racemate, an enantiomer, a diastereomer, mixtures of enantiomers or diastereomers, a tautomer, or a pharmacologically acceptable acid addition salt thereof, and

a solvent selected from the group consisting of water, ethanol and a mixture of water and ethanol.

**2. (Original)** A pharmaceutical composition according to claim 1, wherein  $X^-$  denotes an anion selected from chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate.

**3. (Canceled)**

4. **(Original)** A pharmaceutical composition according to claim 1, wherein in the compound of formula **1**,  $X^-$  is a negatively charged anion selected from chloride, bromide, 4-toluenesulphonate and methanesulphonate.
5. **(Original)** A pharmaceutical composition according to claim 1, wherein in the compound of formula **1**,  $X^-$  denotes bromide.
6. **(Canceled)**
7. **(Currently Amended)** A pharmaceutical composition according to claim 1, wherein **2** is selected from enprofylline, roflumilast, ~~AWD-12-281~~, (N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide), N-(3,5-dichloro-1-oxo-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide and the tricyclic nitrogen heterocycles of formula **2a**.
8. **(Previously presented)** A pharmaceutical composition according to claim 1, wherein the weight ratio of **1** to **(2)** is in the range from 1:100 to 100:1.
9. **(Previously presented)** A pharmaceutical composition according to claim 1, wherein the weight ratio of **1** to **(2)** is in the range from 1:80 to 80:1.
10. **(Previously presented)** A pharmaceutical composition according to claim 1, wherein a single dose for administration corresponds to a dose of the active substance combination **1** and **(2)** of 0.01 to 10000 $\mu$ g
11. **(Previously presented)** A pharmaceutical composition according to claim 1, wherein a single dose for administration corresponds to a dose of the active substance combination **1** and **(2)** of 0.1 to 2000 $\mu$ g.
12. **(Canceled)**
13. **(Previously presented)** A pharmaceutical composition according to claim 1, wherein it is a formulation selected from propellant-containing inhalable aerosols and propellant-free inhalable solutions or suspensions.

**14. – 18. (Canceled)**

- 19. (Previously presented)** A pharmaceutical composition according to claim 13, wherein it is a propellant-containing inhalable aerosol which contains **1** and **(2)** in dissolved or dispersed form.
- 20. (Original)** A propellant-containing inhalable aerosol according to claim 19, containing a propellant gas selected from a hydrocarbon or halohydrocarbon.
- 21. (Original)** A propellant-containing inhalable aerosol according to claim 19, containing a propellant gas selected from n-propane, n-butane, isobutene, chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
- 22. (Original)** A propellant-containing inhalable aerosol according to claim 20, wherein the propellant gas is TG134a, TG227, or a mixture thereof.
- 23. (Previously presented)** A propellant-containing inhalable aerosol according to claim 19, which further comprises one or more other ingredients selected from cosolvents, stabilisers, surfactants, antioxidants, and lubricants.
- 24. (Previously presented)** A propellant-containing inhalable aerosol according to claim 19, wherein it contains up to 5 wt.-% of active substance **1** and/or **(2)**.
- 25. (Previously presented)** A pharmaceutical composition according to claim 1, wherein ~~it~~ the composition is a propellant-free inhalable solution or suspension.
- 26. (Original)** An inhalable solution or suspension according to claim 25, wherein the pH is 2 - 7.
- 27. (Original)** An inhalable solution or suspension according to claim 25, wherein the pH is 2 – 5.

28. **(Previously presented)** A pharmaceutical composition according to claim 1, wherein the composition further comprises an acid selected from hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and propionic acid or mixtures thereof.
29. **(Previously presented)** An inhalable solution or suspension according to claim 25, which contains at least one co-solvent or excipient.
30. **(Previously presented)** An inhalable solution or suspension according to claim 29, containing a co-solvent selected from co-solvents which contain hydroxyl groups or other polar groups.
31. **(Original)** An inhalable solution or suspension according to claim 29, containing a co-solvent selected from isopropyl alcohol, propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
32. **(Original)** An inhalable solution or suspension according to claim 29, containing an excipient selected from surfactants, stabilisers, complexing agents, antioxidants and/or preservatives, flavorings, pharmacologically acceptable salts and/or vitamins.
33. **(Original)** An inhalable solution or suspension according to claim 32, containing a complexing agent selected from edetic acid or a salt of edetic acid.
34. **(Original)** An inhalable solution or suspension according to claim 33 containing sodium edetate.
35. **(Original)** An inhalable solution or suspension according to claim 32, containing an antioxidant selected from ascorbic acid, vitamin A, vitamin E and tocopherols.
36. **(Original)** An inhalable solution or suspension according to claim 32, containing a preservative selected from cetyl pyridinium chloride, benzalkonium chloride, benzoic acid and benzoates.

- 37. (Previously presented)** An inhalable solution or suspension according to claim 29, containing, in addition to the substances **1** and **(2)** and the solvent, only benzalkonium chloride and sodium edetate.
- 38. (Previously presented)** An inhalable solution or suspension according to claim 29, containing, in addition to the substances **1** and **(2)** and the solvent, only benzalkonium chloride.
- 39. – 42. (Canceled)**
- 43. (Original)** A method of treating an inflammatory or obstructive disease of the respiratory tract comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 1.
- 44. (Previously presented)** A composition according to claim 1, further comprising a pharmaceutically acceptable organic or inorganic acid.